NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
22 6월 2023 - 5:05AM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage
biopharmaceutical company committed to discovering and developing
novel, first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced the presentation of a
poster that defines the mechanism of NC525-induced apoptosis of
leukemic cells, but not healthy hematopoietic cells, at the
Federation of Clinical Immunology Societies (FOCIS) annual meeting
in Boston. NC525 is a humanized monoclonal antibody (mAb) that
specifically binds to LAIR-1 and is being developed for the
treatment of advanced myeloid leukemias, including acute myeloid
leukemia (AML), myelodysplastic syndrome and chronic myelomonocytic
leukemia (CMML).
“Our pre-clinical models showed that NC525 specifically
eradicates leukemic stem cells (LSCs) and blast cells, while
preserving healthy hematopoietic cells,” said Solomon Langermann,
Ph.D., NextCure’s chief scientific officer. “The data presented in
the poster define the mechanism that leads to specific induction of
apoptosis in leukemic cells, but not in healthy immune cells. We
look forward to continuing NC525’s clinical development and
providing an update on the trial in the fourth quarter of this
year.”
NC525, a humanized LAIR-1 mAb, targets and destroys AML blasts
and LSCs. AML remains incurable for most patients with current
therapies. High expression of LAIR-1 is seen on leukemic stem cells
and blast cells, where it plays a role in survival of these cancer
cells. LAIR-1 expression is relatively lower on normal
hematopoietic stem cells and does not play a role in survival of
normal immune cells, making it an ideal anti-leukemic target. The
current Phase 1 study is an open-label, non-randomized, dose
escalation trial to determine safety and tolerability of NC525 in
adult patients with relapsed or refractory AML.
Details of the poster presentation are as follows:
Title: LAIR-1 Signal Transduction Determines
Leukemic Cell FateAbstract Number:
W189Session Date: Wednesday, June 21,
2023Session Time: 7:30 AM - 7:30 PM ET
About NextCure, Inc.NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases. Through our proprietary
FIND-IO™ platform, we study various immune cells to discover and
understand targets and structural components of immune cells and
their functional impact in disease in order to develop
immunomedicines. Our initial focus is to bring hope and new
treatments to patients who do not respond to current cancer
therapies, patients whose cancer progresses despite treatment and
patients with cancer types not adequately addressed by available
therapies. http://www.nextcure.com
Cautionary Statement Regarding Forward-Looking
StatementsStatements made in this press release that are
not historical facts are forward-looking statements. Words such as
“expects,” “believes,” “intends,” “hope,” “forward” and similar
expressions are intended to identify forward-looking statements.
Examples of forward-looking statements in this press release
include, among others, statements about NextCure’s plans,
objectives, and intentions with respect to the discovery of
immunomedicine targets and the discovery and development of
immunomedicines. Forward-looking statements involve substantial
risks and uncertainties that could cause actual results to differ
materially from those projected in any forward-looking statement.
Such risks and uncertainties include, among others: our limited
operating history and no products approved for commercial sale; our
history of significant losses; our need to obtain additional
financing; risks related to clinical development, including that
early clinical data may not be confirmed by later clinical results;
risks that pre-clinical research may not be confirmed in clinical
trials; risks related to marketing approval and commercialization;
and the unproven approach to the discovery and development of
product candidates based on our FIND-IO platform. More detailed
information on these and additional factors that could affect
NextCure’s actual results are described in NextCure’s filings with
the Securities and Exchange Commission (the “SEC”),
including NextCure’s most recent Form 10-K and subsequent Form
10-Q. You should not place undue reliance on any
forward-looking statements. NextCure assumes no
obligation to update any forward-looking statements, even if
expectations change.
Investor InquiriesTimothy Mayer, Ph.D.NextCure,
Inc.Chief Operating Officer(240) 762-6486IR@nextcure.com
NextCure (NASDAQ:NXTC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
NextCure (NASDAQ:NXTC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024